We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biodegradable Nanoscaffolds Improve Chances for Stem Cell Therapies

By LabMedica International staff writers
Posted on 15 Nov 2018
The therapeutic potential of biodegradable nanoscaffolds made from manganese dioxide (MnO2) for advanced stem cell transplantation and neural tissue engineering was discussed favorably in a recent paper.

Stem cell transplantation, as a promising treatment for central nervous system diseases, has been hampered by crucial issues such as a low cell survival rate, incomplete differentiation, and limited neurite outgrowth in vivo. More...
Inorganic and carbon-based nanoscaffolds designed to support and improve stem cell growth have been handicapped by their non-biodegradability and restricted biocompatibility, thereby delaying their wide clinical applications. On the contrary, MnO2 nanomaterials have proven to be biodegradable in other bio-applications such as cancer therapies, with MRI active Mn2+ ions as a degradation product.

Investigators at Rutgers University (New Brunswick, NJ, USA) designed nanoscaffolds that mimicked the natural tissue microenvironment to deliver physical and soluble cues. They took advantage of the biodegradability of MnO2 to incorporate its unique physiochemical properties into nano-sized structures for stem cell-based tissue engineering. The result, as described in the August 8, 2018, online edition of the journal Nature Communications was MnO2 nanomaterials-based three-dimensional hybrid nanoscaffolds that better regulated stem cell adhesion, differentiation into neurons, and neurite outgrowth in vitro and enabled enhanced stem cell transplantation benefits in vivo.

These biodegradable MnO2 nanoscaffolds could potentially serve as powerful tools for improving stem cell transplantation and advancing stem cell therapy.

"It has been a major challenge to develop a reliable therapeutic method for treating central nervous system diseases and injuries," said senior author Dr. KiBum Lee, professor of chemistry and chemical biology at Rutgers University. "Our enhanced stem cell transplantation approach is an innovative potential solution."

Related Links:
Rutgers University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Drug Testing Assays
Atellica DT 250 Analyzer
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.